Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | FDPS | P14324 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12352563 | 0.98 | CA1 (0.44) | CA1ACE2L3MBTL1CHEK1FFAR1 | |
| SCHEMBL16664155 | 0.85 | CA1 (0.50) | CA1ACE2L3MBTL1FFAR1FFAR4 | |
| SCHEMBL16417923 | 0.84 | HSD17B10 (0.48) | CA1ACE2L3MBTL1FFAR1FFAR4 | |
| SCHEMBL19364611 | 0.84 | HSD17B10 (0.48) | CA1ACE2L3MBTL1FFAR1FFAR4 | |
| SCHEMBL10290443 | 0.84 | CHEK1 (0.38) | CHEK1FFAR1CNR2GPR84 | |
| SCHEMBL20445091 | 0.83 | L3MBTL1 (0.53) | CA1ACE2L3MBTL1FFAR4MEN1 | |
| SCHEMBL27650965 | 0.83 | L3MBTL1 (0.53) | CA1ACE2L3MBTL1FFAR4MEN1 | |
| SCHEMBL12352198 | 0.83 | L3MBTL1 (0.53) | CA1ACE2L3MBTL1FFAR4MEN1 | |
| SCHEMBL12351438 | 0.83 | CA1 (0.52) | CA1ACE2L3MBTL1FFAR1FFAR4 | |
| SCHEMBL10290410 | 0.83 | ALDH1A1 (0.45) | CA1CHEK1FFAR1CNR2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802939-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | CA1 1574/4885ACE2 176/4885L3MBTL1 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.